{"description":"Causes of death were recorded as adverse events. Other adverse events were not recorded in this study.","eventGroups":[{"deathsNumAffected":19,"deathsNumAtRisk":52,"description":"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.\n\nTRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.\n\ncyclophosphamide: Given IV\n\nbusulfan: Given IV\n\ntacrolimus: Given IV or PO\n\nmethotrexate: Given IV\n\ncytogenetic analysis: Correlative studies\n\nflow cytometry: Correlative studies\n\npharmacological study: Correlative studies\n\npharmacogenomic studies: Correlative studies\n\nperipheral blood stem cell transplantation: Undergo PBPC transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":19,"seriousNumAtRisk":52,"title":"Treatment (Cyclophosphamide, Busulfan, Transplant)"}],"frequencyThreshold":"5","seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52}],"term":"graft-versus-host disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":52}],"term":"Recurrent or progressive malignancy"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52}],"term":"Infection associated with graft-versus-host disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52}],"term":"infection not associated with graft-versus-host disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52}],"term":"Secondary malignancy"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52}],"term":"suicide"}],"timeFrame":"Up to 3 years after enrollment"}